Hence, TCDD may inhibit growth factor-driven EGFR signal transduction in early stages of breast cancer, whereas it is probably ineffective in doing so in advanced stages, when TCDD-activated AHR may dominate and drive tumor progression. Here, EGFR is linked to neoplasm.